Collaborative Pediatric Critical Care Research Network - Clinical Site

项目总结/摘要-洛杉矶儿童医院 此申请表详细说明了洛杉矶儿童医院（CHLA）的资质、兴趣和承诺。 成为协作儿科重症监护研究网络（CPCCRN）的成员。 CHLA及其重症监护部门的研究人员是儿科机械领域的国际专家， 呼吸机、小儿急性呼吸窘迫综合征（PARDS）、信息学和数据科学。博士领导 Khemani（PI）和Newth博士（Co-I），多学科CHLA呼吸研究小组及其成员 领导了PARDS的大型多中心观察性研究（PARDIE研究，145个国际ICU）， 率先制定了与机械通气和PARDS相关的国际实践指南。这一群体 目前正在进行一项高度创新的单中心临床试验， 针对小儿ARDS的肺和膈肌保护性通气，包括全面的 评估ICU后发病率。这些独特的资格和专业知识将极大地丰富科学知识 CPCCRN内部知识的严谨性和广度。此外，其他CHLA研究人员是数据的先驱， 科学，神经重症监护和实施科学，并将把这种专业知识的CPCCRN。CHLA是 在合作研究的最前沿，有几个教师在儿科急性 肺损伤和脓毒症研究者网络（PALISI），儿科神经重症监护研究小组，以及 多中心数据协作，如VPS、VPICU和PICU数据协作。这些专业知识 强调了我们的教师在研究网络中高度协作以实现共同目标的能力。是 因此，毫不奇怪，CHLA是众多多中心临床试验中招募人数最多的， 儿科重症监护的观察性研究。为了进一步提高我们招募大量 为了将不同的患者纳入CPCCRN研究，我们将与儿童医院的辅助研究中心合作， 橙子县（CHOC）。CHOC一直通过参与多中心合作研究， PALISI网络超过10年，并在临床试验中取得了非常高的入组率。 通过我们的两个中心，我们可以确保在CPCCRN进行的临床试验能够获得独特的 南加州的民族、种族和社会经济多样性，包括> 50%的患者为 西班牙裔。这对于提议的脓毒症免疫调节临床试验至关重要， 遗传、表观遗传、环境和社会经济因素可能对治疗产生影响， 结果。我们的网站有几个非常有才华的教师和初级研究人员谁不仅将有助于 CPCCRN的成功，但可以进一步指导和发展成为未来的思想领袖， 临床/翻译研究人员通过CPCCRN。CHLA完全致力于成为一个参与和高度 CPCCRN的生产成员，并执行申请中描述的临床试验。

PROJECT SUMMARY/ABSTRACT – Children’s Hospital Los Angeles This application details the qualifications, interest and commitment of Children’s Hospital Los Angeles (CHLA) to be a member of the Collaborative Pediatric Critical Care Research Network (CPCCRN). CHLA and its investigators in the division of critical care are international experts in pediatric mechanical ventilation, Pediatric Acute Respiratory Distress Syndrome (PARDS), informatics and data science. Led by Dr. Khemani (PI) and Dr. Newth (Co-I), the multi-disciplinary CHLA respiratory research group and its members have led large multi-center observational studies in PARDS (PARDIE study, 145 international ICUs), and have spearheaded international practice guidelines related to mechanical ventilation and PARDS. This group is currently running a highly innovative single center clinical trial using a computerized decision support tool targeting lung and diaphragm protective ventilation in pediatric ARDS, which includes comprehensive assessment of post-ICU morbidity. These unique qualifications and expertise will greatly enrich the scientific rigor and breadth of knowledge within the CPCCRN. In addition, other CHLA investigators are pioneers in data science, neurocritical care and implementation science, and will bring this expertise to the CPCCRN. CHLA is at the forefront of collaborative research, with several faculty holding leadership positions in the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network, the Pediatric Neurocritical Care Research Group, and multi-center data collaboratives such as VPS, VPICU, and the PICU Data Collaborative. This expertise underscores our faculty’s ability to be highly collaborative in a research network to achieve common goals. It is therefore not surprising that CHLA has been the highest enroller in a multitude of multi-center clinical trials and observational studies in pediatric critical care. To further enhance our ability to recruit a large number of diverse patients into the CPCCRN studies, we will partner with an ancillary site at Children’s Hospital of Orange County (CHOC). CHOC has been participating in multi-center collaborative research through the PALISI network for over 10 years and has also achieved remarkably high enrollment rates in clinical trials. Through our two centers, we can ensure that the clinical trial(s) conducted in the CPCCRN capture the unique ethnic, racial, and socio-economic diversity of Southern California which includes > 50% of patients being of Hispanic ethnicity. This is imperative for the proposed clinical trial on immune-modulation in sepsis, given the impact that genetic, epigenetic, environmental, and socio-economic factors may have on treatment and outcomes. Our site has several highly talented faculty and junior investigators who will not only contribute to the success of the CPCCRN but can be further mentored and developed into future thought leaders and clinical/translational researchers through the CPCCRN. CHLA is fully committed to be an engaged and highly productive member of the CPCCRN and execute the clinical trial described in the application.